1. Introduction
Allergic airway inflammation (AAI) is a common respiratory disorder characterized by persistent inflammation of the airways, currently affecting an estimated 358 million individuals globally and representing a substantial worldwide health challenge [
1]. From a pathological perspective, its primary features encompass not only this persistent airway inflammation but also structural remodeling of airway tissues, impairment of epithelial barrier integrity, abnormal proliferation of goblet cells, and dysregulated production and secretion of mucus [
2]. The pathogenesis of allergic airway inflammation (AAI) is driven by a complex network of inflammatory and immune factors, where a precisely regulated balance among inflammation, immunity, and metabolism is essential for preserving systemic homeostasis [
3]. Notably, inflammatory cytokines including IL-4, IL-5, IL-13, and IL-33 are frequently overexpressed in AAI, contributing to the amplification of allergic responses, exacerbation of airway inflammation, and induction of airway hyperresponsiveness [
4]. Concomitantly, aberrant lung function parameters such as elevated airway resistance and reduced dynamic compliance are tightly linked to the airway pathological remodeling triggered by these cytokines [
5]. It is often triggered by environmental factors such as allergens, pollutants, and climatic conditions [
6,
7]. Among them, cold exposure is recognized as one of the risk factors for AAI attacks. Epidemiological studies have shown that cold exposure can significantly increase the emergency visit rate and hospitalization rate of AAI patients, but the underlying mechanism remains unclear [
8,
9].
Ferroptosis is a newly identified type of iron-dependent, regulated cell death [
10]. Its molecular mechanisms mainly involve multiple aspects such as iron metabolism imbalance, enhanced lipid peroxidation, and impaired function of the antioxidant system (e.g., glutathione peroxidase 4, GPX4) [
11]. An increasing number of studies have demonstrated that ferroptosis plays a key role in the pathophysiological processes of various lung diseases [
12]. For instance, in acute lung injury, ferroptosis of alveolar epithelial cells could exacerbate inflammatory responses and lung tissue damage [
13]. In chronic obstructive pulmonary disease (COPD), cigarette smoke extract could promote disease progression by inducing ferroptosis in airway epithelial cells [
14]. Additionally, recent studies have revealed abnormal iron metabolism and elevated levels of lipid peroxidation products in the airway tissues of AAI patients, suggesting that ferroptosis may be involved in the pathogenesis of AAI [
15]. To specifically inhibit this pathway, pharmacological tools such as ferrostatin-1 (Fer-1) have been developed. Fer-1 is a specific ferroptosis inhibitor. It blocks the lipid peroxidation chain reaction by eliminating lipid free radicals, inhibits lipoxygenase, and indirectly regulates iron metabolism to reduce ROS generation, protecting the integrity of cell membranes to prevent ferroptosis [
16]. With its high specificity and low toxicity, it is widely used in research on the mechanism of diseases related to ferroptosis. Therefore, leveraging such tools, investigating whether cold exposure exacerbates AAI symptoms by affecting ferroptosis would be of great significance for clarifying the potential mechanisms underlying the impact of climatic factors on AAI and developing new preventive strategies.
In this study, an ovalbumin (OVA)-sensitized and challenged murine model was employed, which recapitulated several hallmark features of AAI, including Th2 inflammation, airway hyperresponsiveness, mucus hypersecretion, and tissue remodeling. Using this model, we established a cold-exposed AAI group and confirmed that cold exposure significantly aggravated AAI symptoms in mice. To explore whether this exacerbation was mediated through ferroptosis, key ferroptosis-related indicators were assessed, including glutathione peroxidase 4 (GPX4) expression and mitochondrial ultrastructure. Furthermore, the ferroptosis inhibitor ferrostatin-1 (Fer-1) was administered to examine whether inhibiting ferroptosis could mitigate the cold-induced worsening of AAI. Collectively, our findings demonstrated that cold exposure exacerbated AAI, at least in part, by enhancing ferroptosis. This study elucidated a mechanistic link among cold exposure, ferroptosis, and AAI progression, offering a novel theoretical foundation and potential therapeutic targets for managing cold exposure-aggravated allergic airway conditions. It is important to note that this model induces a robust, pan-lung allergic-type inflammation, in contrast to the more bronchial-centric pathology often observed in human asthma. Nonetheless, the shared core inflammatory pathways and environmental triggers make this system highly valuable for dissecting mechanisms that may also operate in the more anatomically restricted human disease.
2. Materials and Methods
2.1. Animal Model Establishment
This study conducted animal experiments using female BALB/c mice (6–8 weeks old). All animal experiments were carried out in accordance with the guidelines approved by the Animal Protection and Use Review Committee of Jilin University and were approved by the Animal Ethics Committee of the School of Basic Medicine, Jilin University (No. 2024-369). All the animals were housed in a Specific Pathogen Free (SPF) environment with controlled temperature (22 ± 2 °C) and humidity (50 ± 10%), and a 12-h light/dark cycle. The grouping of animal experiments was as follows: RT-NC group: room temperature control group; 10-NC group: only the 10 °C exposure treatment group; 4-NC group: only the 4 °C exposure treatment group; RT-AAI group: the group that was sensitized by OVA and challenged at room temperature; 10-AAI group: the group that received 10 °C cold exposure and was sensitized by OVA and challenged; 4-AAI group: the group that received 4 °C cold exposure and was sensitized by OVA and challenged; 4-AAI-Fer-1 group: the group that received 4 °C cold exposure and was sensitized by OVA, followed by intraperitoneal injection of Fer-1. The specific procedures for establishing animal models were as follows: on days 0, 7, and 14, the AAI mice (RT-AAI, 10-AAI, 4-AAI, 4-AAI-Fer-1, n = 6) were intraperitoneally injected with Al(OH)3 (2.5 μL/g, Cat#60749ES10, Yeasen, Shanghai, China) and OVA (2.5 μg/g, Cat#A5503, Sigma-Aldrich, St. Louis, MO, USA) for sensitization (the NC group was intraperitoneally injected with an equal volume of PBS), and on days 21–23, the AAI mice were challenged with OVA nebulization (the NC group was nebulized with an equal volume of PBS). Mice in the 4-AAI-Fer-1 group received intraperitoneal injections of Fer-1 (1 mg/kg, Cat# HY-100579, MCE, Dallas, TX, USA) on days 14 and 21, respectively. Starting from day 0, the corresponding groups of mice were subjected to low-temperature treatment at 10 °C (10-NC and 10-AAI) or 4 °C (4-NC, 4-AAI, and 4-AAI-Fer-1) for 4 h every day. On day 24, all mice were euthanized and samples were collected.
Animals were euthanized by exsanguination under general anaesthesia with isoflurane (Cat#C153359, Aladdin, Shanghai, China).
2.2. Cytokine Detection
The expression levels of IL-4, IL-5, IL-13, and IL-33 in the serum and lung tissues of mice were quantitatively detected using ELISA kits (Cat#EK204, Cat#EK205, Cat#EK213, Cat#EK233, Multi Sciences, Hangzhou, China). All procedures were carried out according to the instructions provided by the manufacturer.
2.3. PCR Array and Quantitative Real-Time PCR (qRT-PCR) Validation
Lung tissue total RNA was isolated with TRIzol reagent (Cat#DP424, Tiangen Biotech, Beijing, China), adhering to the manufacturer-provided protocol. Subsequently, cDNA synthesis was executed using a reverse transcription kit, following the recommended procedure. Gene expression profiling was analyzed by Death screening PCR Array (Cat#WC-MRNA0358-M, Wcgene Biotech, Shanghai, China), according to the manufacturer’s protocol. For gene expression quantification, quantitative PCR was conducted with FastStart Universal SYBR Green Master premix (Cat#04913914001, Sigma-Aldrich, USA) and a Fast qPCR System. The standard curve method was applied for data analysis. The primer sequences utilized in this study are detailed in
Table S1.
2.4. Lung Function Measurement
Lung function was assessed with the Buxco lung function testing system, as detailed in prior research [
2]. Briefly, mice were anesthetized and underwent tracheal intubation, following which the endotracheal tube was attached to the system’s spirometer, barometric, and pressure transducers. Airway responsiveness was subsequently evaluated after exposure to escalating concentrations (0, 3.125, 6.25, 12.5, 25 mg/mL) of Acetyl-β-chloromethylcholine (Cat#A2251, Sigma-Aldrich, USA), and lung parameters were automatically recorded by the spirometry system.
2.5. Malondialdehyde (MDA) and Glutathione (GSH) Assay
To evaluate the degree of lipid peroxidation, the MDA and GSH levels in the lung tissue of mice were quantitatively determined using the lipid peroxidation MDA (Cat#A003-1-2, Nanjing Jiancheng, Bioengineering Institute, Nanjing, China) and GSH (Cat#S0053, Beyotime, Shanghai, China) assay kits. The experiment was carried out strictly in accordance with the manufacturer’s instructions.
2.6. Colorimetric Assay (Ferrozine Method) for Iron Ion Content Detection
To quantify ferrous iron (Fe2+) levels in biological samples, a colorimetric assay based on the formation of a purple-colored complex between ferrous ions and Ferene-S was employed (Cat#BC5415, Solarbio, Beijing, China). The resulting complex exhibits a characteristic absorption peak at 562 nm, and its absorbance was directly proportional to the Fe2+ concentration. The absorbance was measured spectrophotometrically, allowing for the determination of ferrous iron level tissue homogenates.
2.7. Western Blot
Mouse lung tissues were harvested into RIPA lysis buffer (Cat#R0010, Solarbio, China) and homogenized thoroughly. Proteins were separated by SDS-PAGE, transferred to a PVDF membrane (Cat#IPVH00005, Merck Millipore, Darmstadt, Germany), and blocked with 5% BSA (Cat#ST023, Beyotime, China) for 2 h. The membrane was then incubated with primary antibodies at 4 °C overnight, washed with TBST, and incubated with HRP-labeled secondary antibody (Cat#RS0008, Immunoway, San Jose, CA, USA) for 1 h. The primary antibodies used were: Anti-GPX4 pAb (Cat#30388-1-AP, Proteintech, China), Anti-ACSL4 pAb (Cat#22401-1-AP, Proteintech, Wuhan, China), Anti-FTL pAb (Cat#10727-1-AP, Proteintech, China), and Anti-β-actin pAb (Cat# 20536-1-AP, Proteintech, China). Protein signals were detected and quantified using ImageJ (version 1.53t).
2.8. Transmission Electron Microscope (TEM)
Lung tissues fixed in 2.5% glutaraldehyde were rinsed, post-fixed in 1% osmium tetroxide, dehydrated (gradient ethanol), infiltrated, and embedded in epoxy resin. Ultrathin sections were stained with uranyl acetate and lead citrate; then, they were observed via a transmission electron microscope, images were captured, and structures were analyzed.
2.9. Immunohistochemistry Staining (IHC)
Fresh tissues fixed in 4% paraformaldehyde (Cat#P0099, Beyotime, China) were dehydrated, cleared, and paraffin-embedded; 4–5 μm sections on polyline slides were baked at 60 °C, then dewaxed, hydrated, and PBS-washed. Then, they were incubated with mucin 5AC (MUC5AC) antibodies (Cat#20725-1-AP, Proteintech, China), rewarmed, PBS-washed, and then HRP-secondary antibodies (Cat#RS0008, Immunoway, USA) were added. They were then PBS-washed and fresh DAB was developed for 3–10 min, followed by hematoxylin counterstaining, 1% HCl-ethanol differentiation, and bluing. Finally, they were dehydrated, cleared, mounted, microscopically observed, and quantified via Image-ImageJ (version 1.53t).
2.10. Hematoxylin-Eosin Staining (H&E)
Paraffin sections were dewaxed in xylene, hydrated through gradient ethanol, stained with hematoxylin for 5–10 min, differentiated with 1% hydrochloric acid-ethanol, and blued with tap water. Then they were stained with eosin for 1–3 min, dehydrated with gradient ethanol, cleared in xylene, and mounted with neutral gum. They were observed under a light microscope.
2.11. Alcian Blue-Periodic Acid-Schiff Staining (AB-PAS)
Dewaxed and hydrated sections were stained with alcian blue solution (pH 2.5) for 30 min, rinsed, oxidized with periodic acid for 5–10 min, rinsed again, then treated with Schiff reagent for 15–30 min. Then they were counterstained with hematoxylin lightly, dehydrated, cleared, and mounted. Acid mucins appeared blue and neutral mucins magenta.
2.12. Masson’s Trichrome Staining (Masson)
Dewaxed and hydrated sections were stained with Weigert’s iron hematoxylin for 5–10 min, rinsed, then stained with Biebrich scarlet-acid fuchsin for 5–10 min. After differentiation with phosphomolybdic acid solution, they were stained with aniline blue for 5–10 min, dehydrated quickly, cleared, and mounted. Collagen fibers appeared blue, cytoplasm red, and nuclei black.
2.13. Prussian Blue Staining (Enhance with DAB)
Paraffin sections were dewaxed and then transferred to absolute ethanol I and absolute ethanol II for 5 min each, respectively. The staining solution was prepared by mixing hydrochloric acid and potassium ferrocyanide at a volume ratio of 1:1, and the sections were stained with this solution for 1 h. Subsequently, a DAB stock solution was mixed with the diluent at a volume ratio of 1:50, and the sections were stained with the prepared DAB working solution for 5–10 min. After that, the sections were stained with nuclear fast red for 3–5 min. Finally, the sections were subjected to dehydration and mounting procedures.
4. Discussion
AAI is a prevalent chronic respiratory condition significantly influenced by environmental factors, with cold exposure being a recognized trigger for exacerbations. Numerous epidemiological studies have demonstrated a clear association between extreme temperatures. Among them, cold exposure has long been regarded as a key factor leading to acute exacerbation of the disease [
17,
18]. Cold exposure-induced AAI exacerbations are typically linked to heightened airway inflammation, mucus hypersecretion, and impaired lung function [
19]. However, the molecular mechanism between cold exposure and AAI exacerbation has not been fully elucidated, which limits the development of targeted interventions for such climate-related disease burdens.
Cold exposure can trigger a series of physiological and pathological changes in the respiratory system, and these changes work together to exacerbate AAI. Firstly, cold air directly stimulates the smooth muscles of the airways, causing vasoconstriction and increased muscle tone-this effect is particularly significant in AAI patients who already have airway hyperresponsiveness [
20]. This will lead to an immediate increase in airway resistance, as we observed in the mouse model, a decrease in Cdyn and an increase in RI. Secondly, cold exposure undermines the integrity of the airway epithelial barrier: Low temperatures can damage the tight junction function of epithelial cells, reduce the efficiency of mucosal ciliary clearance, and promote the death of epithelial cells, thereby creating a “leaking” airway microenvironment that provides favorable conditions for allergen penetration and microbial colonization [
17]. The histopathological analysis of this study revealed that cold-exposed AAI mice had severe epithelial damage, goblet cell proliferation and hypersecretion of mucus (confirmed by increased MUC5AC expression and AB-PAS staining results). Thirdly, cold exposure amplifies type 2 inflammatory responses: Our data show that cold stress (especially at 4 °C) significantly upregulates the expression of helper Th2-related cytokines (IL-4, IL-5, IL-13) and the alarm hormone IL-33 in lung tissue. Among them, IL-33 plays a key role in activating type 2 innate lymphocytes (ILC2s) and Th2 cells, forming a positive feedback loop that maintains airway inflammation [
21].
Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, iron accumulation, and mitochondrial damage, has emerged as a critical player in the pathophysiology of various pulmonary diseases, including acute lung injury and COPD [
22,
23,
24]. Increasing evidence suggests that ferroptosis may contribute to airway epithelial damage in AAI, exacerbating inflammation and impairing lung function. Recent studies have highlighted the involvement of altered iron metabolism and elevated lipid peroxidation products in AAI, further implicating ferroptosis in the disease’s progression [
25,
26]. In our study, we observed that cold exposure in AAI mice triggered the hallmark features of ferroptosis in lung tissues, including elevated ACSL4 expression, reduced GPX4 and FTL levels, increased iron deposition, and enhanced lipid peroxidation, as indicated by increased MDA levels. Importantly, inhibition of ferroptosis using Fer-1 significantly alleviated the exacerbation of AAI symptoms, including reductions in airway inflammation, mucus hypersecretion, airway resistance, and histopathological damage. These results confirmed that ferroptosis was a key mediator linking cold exposure to AAI aggravation, highlighting its potential as a therapeutic target. However, it was observed that the efficacy of Fer-1 was not uniform in all pathological manifestations of AAI aggravated by cold exposure. While Fer-1 administration robustly reversed the core biochemical signatures of ferroptosis, its impact on other endpoints was more moderate. Notably, the improvements in lung function parameters, though statistically significant, were partial. This spectrum of efficacy suggests that ferroptosis acts as a predominant driver of acute epithelial injury, oxidative stress, and the secretory phenotype in the cold-stressed airway, processes directly linked to mucus pathology. In contrast, the pathways leading to sustained airway dysfunction and fibrotic remodeling appear to be more complex and multifactorial, involving mechanisms beyond acute ferroptosis that are not fully corrected by its short-term inhibition. Consequently, the modest restoration of lung function aligns with Fer-1’s role as a specific inhibitor targeting a key upstream pathogenic event rather than a broad-spectrum agent. This understanding positions the inhibition of ferroptosis not as a standalone remedy for immediate functional recovery, but as a promising adjunctive strategy. It holds particular potential for mitigating the epithelial damage and mucus hypersecretion that characterize disease exacerbations, thereby complementing existing therapies within a combined management approach for environmental trigger-induced airway inflammation. While our study confirmed ferroptosis as the dominant cell death pathway linking cold exposure to AAI exacerbation, we acknowledge that apoptosis and necrosis may also be involved in the pathological process—consistent with the preliminary observations from PCR array and TUNEL staining. However, these modalities were not fully characterized in the current work, as our focus was on validating the ferroptosis-mediated mechanism. Future studies will build on the current model to explore the crosstalk between ferroptosis, apoptosis, and necrosis which may provide a more comprehensive understanding of the molecular network underlying cold-induced AAI aggravation and inform the development of multi-target therapeutic strategies.
Several limitations of this study should be acknowledged. First, our investigations were conducted in an OVA-induced mouse model of AAI. While this model recapitulated several key features of human AAI—such as Th2 inflammation, airway hyperresponsiveness, and remodeling—it represented a pan-lung inflammatory response rather than a disease confined strictly to the airways. A second limitation was the absence of OVA-specific bronchoprovocation testing, which would have allowed us to directly assess antigen-driven airway responsiveness—a defining feature of AAI. Our use of methacholine-induced non-specific AHR captured cumulative airway dysfunction but did not distinguish immune-mediated responses to OVA. Future studies should incorporate OVA-specific bronchoprovocation to validate whether cold exposure exacerbates antigen-specific AHR and whether ferroptosis inhibition modulates this pathway, particularly in humanized models or in vitro systems using primary human airway cells. Third, although we focused on ferroptosis, cold exposure may concurrently engage other forms of regulated cell death (e.g., apoptosis, necroptosis), and potential crosstalk among these pathways warrants further exploration. Further research is needed to explore whether ferroptosis interacts with other forms of regulated cell death. While challenges remain in translating these findings into clinical practice, our study establishes a “cold exposure-ferroptosis-AAI exacerbation” axis, uncovering ferroptosis as a link between environmental cold exposure and allergic airway pathology. The reversal of cold exposure-induced airway inflammation and dysfunction by Fer-1 not only validates ferroptosis as a promising therapeutic target but also opens new avenues for developing interventions aimed at mitigating the climate-related burden of AAI and similar allergic respiratory conditions.